Nothing Special   »   [go: up one dir, main page]

DE69916640D1 - Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe - Google Patents

Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe

Info

Publication number
DE69916640D1
DE69916640D1 DE69916640T DE69916640T DE69916640D1 DE 69916640 D1 DE69916640 D1 DE 69916640D1 DE 69916640 T DE69916640 T DE 69916640T DE 69916640 T DE69916640 T DE 69916640T DE 69916640 D1 DE69916640 D1 DE 69916640D1
Authority
DE
Germany
Prior art keywords
immunological
active ingredients
medicinal product
delayed active
layers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69916640T
Other languages
English (en)
Other versions
DE69916640T2 (de
Inventor
Gerard Alaux
Frederic Andre
Alain Cuine
Gareth Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of DE69916640D1 publication Critical patent/DE69916640D1/de
Publication of DE69916640T2 publication Critical patent/DE69916640T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69916640T 1998-10-16 1999-10-12 Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe Expired - Lifetime DE69916640T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9812977A FR2784583B1 (fr) 1998-10-16 1998-10-16 Composition pharmaceutique a residence gastrique et a liberation controlee
FR9812977 1998-10-16
PCT/FR1999/002443 WO2000023045A1 (fr) 1998-10-16 1999-10-12 Composition pharmaceutique a residence gastrique et a liberation controlee

Publications (2)

Publication Number Publication Date
DE69916640D1 true DE69916640D1 (de) 2004-05-27
DE69916640T2 DE69916640T2 (de) 2005-03-31

Family

ID=9531635

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69916640T Expired - Lifetime DE69916640T2 (de) 1998-10-16 1999-10-12 Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe

Country Status (12)

Country Link
US (1) US6861072B1 (de)
EP (1) EP1121099B1 (de)
JP (1) JP2002527464A (de)
AT (1) ATE264666T1 (de)
AU (1) AU774723B2 (de)
CA (1) CA2347105C (de)
DE (1) DE69916640T2 (de)
DK (1) DK1121099T3 (de)
ES (1) ES2219062T3 (de)
FR (1) FR2784583B1 (de)
PT (1) PT1121099E (de)
WO (1) WO2000023045A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
KR100685945B1 (ko) 2000-12-29 2007-02-23 엘지.필립스 엘시디 주식회사 액정표시장치 및 그 제조방법
FR2820318B1 (fr) * 2001-02-08 2005-12-23 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
EP1411901B1 (de) 2001-07-04 2010-08-18 Sun Pharma Advanced Research Company Ltd Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
ES2247897B1 (es) * 2003-12-18 2007-05-01 Gat Formulation Gmbh Tabletas con matriz polimerica emulsionada para emision controlada de gases y procedimiento para su fabricacion.
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
EP1957052A2 (de) * 2005-10-25 2008-08-20 Pharmascience Inc. System zur abgabe eines magenretentionsmittels
US7674396B2 (en) * 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
US7879355B2 (en) * 2005-11-08 2011-02-01 Plensat Llc Method and system for treatment of eating disorders
US20110112383A1 (en) * 2005-11-08 2011-05-12 Plensat, Inc Devices, systems and methods for treatment of eating disorders
WO2007080509A2 (en) * 2006-01-12 2007-07-19 Wockhardt Ltd Sustained release compositions of alfuzosin
HUE040311T2 (hu) 2006-04-04 2019-02-28 Kg Acquisition Llc Vérlemezke aggregációt gátló szert és sav inhibitort tartalmazó orális dózisformák
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
AT505225A1 (de) 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
DE102007026037A1 (de) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
JP2012500230A (ja) 2008-08-18 2012-01-05 北京天衡▲薬▼物研究院 胃内滞留薬物放出システム及びその製造方法と使用
US20100249423A1 (en) * 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
KR101137466B1 (ko) * 2009-06-12 2012-04-20 안국약품 주식회사 염산 알푸조신 함유 서방성 정제
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2967352B1 (fr) * 2010-11-12 2012-12-28 Unither Dev Comprime effervescent pour l'administration par voie orale de principes actifs
CN102475690B (zh) * 2010-11-30 2016-06-01 安国药品株式会社 内含盐酸阿夫唑嗪的缓释片剂
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
SG11202113266YA (en) 2019-06-04 2021-12-30 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
DE69613966T2 (de) * 1995-03-17 2002-04-04 The Boots Co., Plc Pharmazeutische zusammensetzungen mit pektin
WO1997047285A1 (en) * 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
NZ334018A (en) * 1996-08-29 1999-06-29 Synthelabo Multilayered controlled release tablet comprising a layer of alfuzosin hydrochloride and at least one layer of hydrophillic polymers
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
FR2762213B1 (fr) * 1997-04-18 1999-05-14 Synthelabo Composition pharmaceutique a retention gastrique
PT1003476E (pt) * 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica

Also Published As

Publication number Publication date
US6861072B1 (en) 2005-03-01
DE69916640T2 (de) 2005-03-31
FR2784583A1 (fr) 2000-04-21
ES2219062T3 (es) 2004-11-16
WO2000023045A1 (fr) 2000-04-27
CA2347105A1 (en) 2000-04-27
EP1121099B1 (de) 2004-04-21
EP1121099A1 (de) 2001-08-08
PT1121099E (pt) 2004-08-31
CA2347105C (en) 2009-09-29
JP2002527464A (ja) 2002-08-27
AU6094799A (en) 2000-05-08
DK1121099T3 (da) 2004-08-09
FR2784583B1 (fr) 2002-01-25
ATE264666T1 (de) 2004-05-15
AU774723B2 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
DE69916640D1 (de) Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe
DE69918310D1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
HUP9904174A2 (hu) Bőrön át történő adagoláshoz szánt gyógyszerkészítmények
AU5680100A (en) Controlled release and taste masking oral pharmaceutical compositions
DE69229949D1 (de) Diltiazem enthaltende arzneimittel mit verzögerter wirkstoffabgabe
AU2925295A (en) A novel drug delivery system
WO2000061115A3 (en) Pharmaceutical formulation comprising amoxycillin
IT1178430B (it) Idrogeli polimerici separati in microfase per il rilascio controllato di materiali bioattivi, quali medicinali, antibiotici, contraccettivi e simili
AU6517496A (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
AU6909800A (en) Metering and packaging of controlled release medication
DE69428862D1 (de) Linsenförmig pharmazeutische Tablette mit verzögerter Freigabe
DE60237372D1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
WO1998009597A3 (en) Cushioning beads and tablet comprising the same capable of forming a suspension
WO2004000389A3 (en) Rapidly dissolving micro-perforator for drug delivery and other applications
NO995313L (no) Mikroartikler nyttige som ultrasoniske kontrastmidler og til levering av legemidler i blodbanen
NO991921L (no) Vannoppl°selig film eller vannoppl°selig sjikt som viser °yeblikkelig fuktbarhet for oral tilf°rsel
PT1227802E (pt) Prepacao de pelicula para libertacao bifasica de substancias farmacologicamente activas ou outras
NO891680L (no) Osmotisk kontinuerlig avgivende oralt avgivelsessystem inneholdende et farmasoeytisk akseptabelt aktivt middel som har forbedrede kjernemembran-adhesjonsegenskaper.
ATE232100T1 (de) Gegen magensaft geschützte omeprazol- mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen
AU3438897A (en) Stable drug form for oral administration and process for the preparation thereof
DE60225481D1 (de) Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung
WO2001013899A3 (de) Wirkstoffhaltiges therapeutisches system mit mindestens zwei polymerhaltigen schichten
CO5011082A1 (es) Formulacion medicamentosa con liberacion controlada de sus- tancia activa
ATE306910T1 (de) Tablette mit verlängerter wirkstoffabgabe im magen
WO2002034240A3 (en) Delayed and sustained release formulations and method of use thereof

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1121099

Country of ref document: EP

Representative=s name: TER MEER STEINMEISTER & PARTNER GBR PATENTANWA, DE